Latest News
The latest and greatest from Flomics
Genomics Scientist ||
Flomics is a fast-growing biotech company founded in 2018 in Barcelona. We are developing a revolutionary liquid biopsy...
Flomics Tackles Lung Cancer Relapse Detection with RNA-Based Liquid Biopsy in European Project LUMINA
Flomics joins the LUMINA project, funded by Eurostars, to apply its RNA-based liquid biopsy technology in the early detection of lung cancer recurrence. By combining transcriptomic and genomic biomarkers with artificial intelligence, the project aims to improve post-treatment monitoring and enable more timely clinical decisions.
BIOTEM project launch: Flomics expands to 7 Cancer types
Flomics will validate its cf-RNA liquid biopsy for 7 cancer types, adding liver and hematological tumors to its early detection pipeline.
Flomics contributes to the discovery of a circulating microRNA signature for PMM2-CDG diagnosis and monitoring
A new study led by researchers from Hospital Sant Joan de Déu (Barcelona) in collaboration with Flomics Biotech was...
Closing meeting with the LiquiDx consortium
On 18th September 2025, the LiquiDx consortium gathered at the Biobanco del Sistema Sanitario Público de Andalucía (BBSSPA)...
Flomics Breakthrough in Liquid Biopsy: RNA & AI Enable Multicancer Early Detection
Flomics Biotech’s liquid biopsy breakthrough enables early detection of colorectal, lung, breast, prostate, and pancreatic cancers using cell.free RNA biomarkers and AI, achieving 92% predictive accuracy and 80% Stage I sensitivity, advancing toward clinical trials for…
Third face-to-face meeting of the LiquiDx project consortium
The consortium led by Flomics Biotech, in which the Biobank of the Andalusian Public Health System (SSPA) and Leitat Technological Center participate, held its second annual coordination meeting at the Parc de Recerca Biomèdica de…
First Freedom-to-operate study completed with the support of ACCIÓ
Flomics Biotech successfully completed a comprehensive Freedom-To-Operate (FTO) study in collaboration with ZBM Patents, confirming that its cfRNA-based liquid biopsy technology is free of patent conflicts. This milestone supports Flomics’ path to commercialization and strengthens its position for strategic European funding opportunities…
Successful Crowdfunding Campaign with Capital Cell
Flomics have officially closed our crowdfunding campaign with Capital Cell! Running from June 18 to July 12, 2024, this campaign has been a testament to the strong belief and support we have toward our mission, proposal, and work.
AGAUR Industrial PhD Grant to Giovanni Asole
‘’Tissue-of-origin deconvolution of the cell-free transcriptome for non-invasive screening of multiple cancer types’’ It is the project titled that has been awarded the AGAUR Industrial PhD Scholarship; Giovanni Asole project co-supervised by Dr. Julien Lagarde (head of bioinformatics…
Press
Flomics Newsletter
Stay up to date with Flomics news, get access to articles related to our services and don’t miss out on the most recent Biotech news and events.
Subscribe below: